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JNKSLC25A13 (citrin or aspartate–glutamate carrier 2) is located in the mitochondrial membrane in the liver and its
genetic deﬁciency causes adult-onset type II citrullinemia (CTLN2). CTLN2 is one of the urea cycle disorders char-
acterized by sudden-onset hyperammonemia due to reduced argininosuccinate synthase activity. This disorder is
frequently accompanied with hepatosteatosis in the absence of obesity and ethanol consumption. However, the
precise mechanism of steatogenesis remains unclear. The expression of genes associated with fatty acid (FA) and
triglyceride (TG) metabolism was examined using liver samples obtained from 16 CTLN2 patients and compared
with 7 healthy individuals. Although expression of hepatic genes associated with lipogenesis and TG hydrolysis
was not changed, themRNAs encoding enzymes/proteins involved in FA oxidation (carnitine palmitoyl-CoA trans-
ferase 1α, medium- and very-long-chain acyl-CoA dehydrogenases, and acyl-CoA oxidase 1), very-low-density li-
poprotein secretion (microsomal TG transfer protein), and FA transport (CD36 and FA-binding protein 1), were
markedly suppressed in CTLN2 patients. Serum concentrations of ketone bodies were also decreased in these pa-
tients, suggesting reduced mitochondrial β-oxidation activity. Consistent with these ﬁndings, the expression of
peroxisome proliferator-activated receptor α (PPARα), a master regulator of hepatic lipid metabolism, was signif-
icantly down-regulated. Hepatic PPARα expressionwas inversely correlatedwith severity of steatosis and circulat-
ing ammonia and citrulline levels. Additionally, phosphorylation of c-Jun-N-terminal kinase was enhanced in
CTLN2 livers, whichwas likely associatedwith lower hepatic PPARα. Collectively, down-regulation of PPARα is as-
sociated with steatogenesis in CTLN2 patients. These ﬁndings provide a novel link between urea cycle disorder,
lipid metabolism, and PPARα.
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Urea cycle disorder can cause hepatic steatosis. It was reported
that liver pathology in 10 children with defects of ureagenesis,
such as carbamoyl-phosphate synthase deﬁciency and ornithine
transcarbamoylase deﬁciency, showed diffuse microvesicular
steatosis mimicking Reye's syndrome [1]. Additionally, suppression
of urea cycle enzymes was observed in juvenile visceral steatosis
mice [2]. These ﬁndings suggest a possible relationship between
urea cycle disorder and disruption of lipid metabolism in the liver.
However, the mechanism by which hepatosteatosis develops in the
patients having urea cycle disorder has not been investigated.
Citrin [SLC25A13, also known as aspartate–glutamate carrier 2
(AGC2)], encoded by the SLC25A13 gene, is a liver-type carrier located
in the inner mitochondrial membrane and plays an important role in
ureagenesis and gluconeogenesis [3–6]. Citrin deﬁciency (CD, also
known as SLC25A13 deﬁciency or AGC2 deﬁciency) is an autosomal re-
cessive disorder caused by mutations in the SLC25A13 gene on chromo-
some 7q21.3, leading inmany cases to neonatal intrahepatic cholestasis
(NICCD; OMIM#605814) and adult-onset type II citrullinemia (CTLN2;
OMIM#603471) [7]. Although CD had been regarded as a hereditary
disease in East Asia [8,9], there are some recent reports of non-Asian
CD patients from US, UK, France, Czech Republic, Canada, and Israel, re-
vealing that CD is a pan-ethnic disorder [10–12]. Humans having
SLC25A13mutations are sometimes asymptomatic probably due to un-
known metabolic adaptation mechanisms. However, sudden onset of
hyperammonemia and neuropsychiatric symptoms, such as uncon-
sciousness and abnormal behavior, due to decreased argininosuccinate
synthase (ASS) activity and impaired urea cycle in the liver, may lead
to the diagnosis of CTLN2 [5,13,14]. The period of ﬁrst appearance of
neurological symptoms is various and some patients undergo ﬁrst
onset of the symptoms at the age of more than 50 years [15]. CTLN2
patients have unique dietary habits that like an afﬁnity for fat-rich
foods and dislike sweets and ethanol [16]. Ethanol consumption,
glycerol infusion, and correction of fat-rich diet may trigger/aggravate
hyperammonemia and encephalopathy in the patients with CD [17,18].
Some CTLN2 patients have experienced pancreatitis and been pointed
out liver dysfunction and hypertriglyceridemia prior to appearance of
neuropsychiatric symptoms [14,19,20]. These diverse clinical features
make the correct and early diagnosis of CD/CTLN2 complicated.
Similarly to other urea cycle disorders, CD is frequently accompanied
by hepatosteatosis. Hepatic ﬁbrosis and increased incidence of hepato-
cellular carcinoma were also reported in CD patients [21,22]. Since he-
patic steatosis sometimes precedes the appearance of neurological
abnormalities, some CD patients may be misdiagnosed as having non-
alcoholic fatty liver disease (NAFLD) [14,20]. Liver histology of CTLN2
patients demonstrated macrovesicular and microvesicular steatosis, in-
ﬁltration of inﬂammatory cells in the lobular and portal areas, and hepa-
tocyte ballooning thatmimics simple steatosis or steatohepatitis [14,20].
We previously reported that CD-related fatty liver showed lower preva-
lence of accompanying obesity, lower body mass index (BMI), higher
prevalence of history of pancreatitis, and higher serum concentrations
of pancreatic secretory trypsin inhibitor compared with conventional
NAFLD livers without the SLC25A13 mutations [20]. However, the
precise mechanism on how hepatic steatosis develops in CD/CTLN2
patients remains unclear.
To address it, the expression levels of the genes associated with
fatty acid/triglyceride (FA/TG) metabolism were examined in
CTLN2 patients having hepatic steatosis. We found that peroxisome
proliferator-activated receptor α (PPARα) and its downstream FA
β-oxidation were signiﬁcantly down-regulated in the livers of CTLN2
patients. Additionally, hepatic PPARα expression was in inverse
proportion to severity of steatosis and circulating ammonia and
citrulline levels. These ﬁndings provide new insights regarding
the association between urea cycle, PPARα signaling, and
hepatosteatosis.2. Materials and methods
2.1. Ethics
This study was carried out in accordance with the 1975 World
Medical Association Helsinki Declaration and was approved by the
Shinshu University School of Medicine ethics committee. Informed
consent was obtained from all patients.
2.2. Patients
Sixteen CTLN2 patients (8 men and 8 women, 38 ± 12 years), who
had been admitted to Shinshu University Hospital between 1998 and
2012 and conﬁrmed the presence of SLC25A13mutations, were exam-
ined in this study. For comparison, 7 healthy living donors for liver
transplantation (4men and 3 women, 40± 8 years), who had been ad-
mitted to Shinshu University Hospital between 2008 and 2012, were
analyzed as normal controls. All of these healthy individuals satisﬁed
the following criteria: 1) the absence of past history of liver disease
and regular intake of alcohol and drugs; 2) the absence of obesity, diabe-
tes, hypertension, and hyperlipidemia; 3) normal liver function tests;
4) normal liver histology; and 5) the absence of SLC25A13mutations.
2.3. SLC25A13 gene mutation analysis
DNA was extracted from peripheral blood using standard methods
[7–9]. Sixteen SLC25A13mutations reported previously were tested by
the polymerase chain reaction (PCR)-restriction fragment length
polymorphismmethod and/ormultiplemethods usingGenescan/SNaP-
shot [7–9].
2.4. Laboratory examination
At the time of admission, blood samples were obtained in a fasting
state and complete blood counts and blood chemistries were determined
by standardmethods [23,24]. Free FAs and ketone bodiesweremeasured
enzymatically (http://www.srl-group.co.jp, SRL, Tokyo, Japan). Hepatic
ASS activity was quantiﬁed in 11 CTLN2 patients as described previously
[25]. Serum concentrations of malondialdehyde (MDA), a typical oxida-
tive stressmarker, weremeasured using a lipid peroxidation colorimetric
assay kit purchased from Oxis International (Beverly Hills, CA, USA).
2.5. Histological analysis
Liver samples in CTLN2 patients were obtained by percutaneous ul-
trasonography (US)-guided biopsy (9 patients) or living donor liver
transplantation (7 patients). Liver samples in healthy liver transplanta-
tion donors were obtained at the time of pre-operative percutaneous
US-guided biopsy. Fragments of liver tissue (5–7mm)were immediate-
ly frozen in liquid nitrogen and stored at−80 °C until RNA extraction.
The remaining tissues were ﬁxed in 10% neutral formalin, embedded
in parafﬁn, cut at 4 μm thickness, and stained with the hematoxylin
and eosin or Azan–Mallory method [23,26]. Histological ﬁndings were
assessed by an independent experienced pathologist in a blinded fash-
ion and scored according to the staging/grading system proposed by
Kleiner et al.[27]. The NAFLD activity score was calculated as the un-
weighted sum of the scores for steatosis (0–3), lobular inﬂammation
(0–3), and ballooning (0–2). The diagnosis of steatohepatitis was
made by the presence of macrovesicular steatosis, hepatocyte balloon-
ing, and lobular inﬂammation [23,26].
2.6. Quantitative mRNA analysis
Total liver RNA was extracted using a RNeasy Mini Kit (QIAGEN,
Hilden, Germany), and 2 μg of RNA was reverse-transcribed using
oligo-dT primers and SuperScript II reverse transcriptase (Invitrogen
Table 1
Clinical characteristics of subjects enrolled in this study.
Normal Mild steatosis Severe steatosis P value
(N = 7) (N = 10) (N = 6) Normal vs mild Normal vs severe Mild vs severe
Age (years) 40 (27–50) 42 (19–52) 33 (21–52) 0.845 0.568 0.515
Male 4 (57%) 6 (60%) 2 (33%) 1.000 0.592 0.608
Height (m) 1.60 (1.53–1.75) 1.63 (1.41–1.75) 1.60 (1.41–1.75) 0.922 0.615 0.786
Weight (kg) 54.7 (53.0–75.0) 50.4 (42.0–68.3) 46.5 (34.0–49.5) 0.121 0.008 0.247
BMI (kg/m2) 22.2 (21.1–23.9) 19.0 (16.2–23.6) 15.9 (14.8–21.5) 0.034 0.013 0.118
Waist (cm) 76 (67–85) 72 (68–76) 60 (58–69) 0.346 0.029 0.025
WBC (/μl) 5370 (3020–7120) 3865 (2620–10,420) 3745 (2300–5610) 0.435 0.190 0.386
Hb (g/dl) 14.0 (12.3–16.0) 13.4 (9.5–15.5) 11.9 (10.5–14.3) 0.438 0.346 0.067
PLT (×104/μl) 24.0 (19.9–34.1) 19.4 (6.8–25.7) 18.8 (8.6–25.6) 0.107 0.347 1.000
TP (g/dl) 6.8 (6.1–7.5) 6.7 (5.9–7.2) 6.1 (5.6–7.0) 0.375 0.132 0.192
ALB (g/dl) 4.1 (4.0–4.5) 4.0 (3.1–4.5) 3.5 (3.1–3.7) 0.697 0.057 0.007
T-BIL (mg/dl) 0.60 (0.35–0.81) 0.82 (0.31–1.42) 0.95 (0.52–1.70) 0.663 0.186 0.356
AST (IU/l) 20 (13–21) 40 (18–123) 69 (20–205) 0.010 0.022 0.832
ALT (IU/l) 19 (11–22) 40 (20–132) 66 (20–126) 0.009 0.024 0.761
ALP (IU/l) 180 (81–290) 297 (90–800) 411 (70–521) 0.153 0.259 0.828
GGTP (IU/l) 35 (10–69) 103 (24–376) 185 (21–343) 0.212 0.190 0.914
AMY (IU/l) 71 (50–90) 101 (42–177) 59 (23–103) 0.355 0.848 0.196
BUN (mg/dl) 15 (8–15) 15 (13–23) 16 (13–28) 0.439 1.000 0.659
CRE (mg/dl) 0.6 (0.4–0.7) 0.5 (0.3–0.8) 0.6 (0.3–0.8) 0.632 0.785 0.823
TG (mg/dl) 100 (50–149) 98 (53–684) 223 (78–918) 0.494 0.189 0.525
FFA (μEq/l) 696 (500–802) 801 (530–1170) 818 (632–1056) 0.526 0.391 0.745
TC (mg/dl) 156 (137–189) 203 (112–259) 149 (113–216) 0.321 0.775 0.699
LDL-C (mg/dl) 89 (78–122) 90 (37–163) 65 (32–163) 0.908 0.464 0.396
FBS (mg/dl) 99 (89–106) 94 (77–129) 101 (78–145) 0.958 0.667 0.813
NH3 (μg/dl) 25 (20–32) 172 (39–239) 162 (35–224) 0.003 0.008 0.813
Citrulline (nmol/ml) 20 (15–23) 215 (86–498) 373 (200–1542) 0.003 0.013 0.952
Hepatic ASS activity
(units/mg protein)
– 0.005 (0.001–0.024) 0.002 (0.0003–0.007) – – 0.300
Results are expressed as median (range) or number (percentage). Comparisons between groups were made using the Kruskal–Wallis test followed by the Mann–Whitney U-test with
Bonferroni's correction or the Fisher's exact probability test. Hepatic argininosuccinate synthase (ASS) activities were measured in 11 CTLN2 patients (6 mild and 5 severe steatosis pa-
tients) as described previously [25]. Normal value of hepatic ASS activity was 0.033 ± 0.012 units/mg protein [32]. A p value of less than 0.05 was underlined. BMI, body mass index;
WBC, white blood cell; Hb, hemoglobin; PLT, platelet; TP, total protein; ALB, albumin; T-BIL, total bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline
phosphatase; GGTP, γ-glutamyltransferase; AMY, amylase; BUN, blood urea nitrogen; CRE, creatinine; TG, triglyceride; FFA, free fatty acid; TC, total cholesterol; LDL-C, low-density-lipo-
protein cholesterol; FBS, fasting blood sugar; NH3, ammonia.
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of mRNAs were quantiﬁed by real-time PCR using a SYBR Premix Ex
TaqTM II (Takara Bio, Otsu, Japan) on a Thermal Cycler Dice TP800 sys-
tem (Takara Bio). The primer sequences are shown in Supplementary
Table 1, whose speciﬁcity was conﬁrmed by nucleotide blast (http://
blast.ncbi.nlm.nih.gov/Blast.cgi). HepaticmRNA levelswere determined
using the ΔΔCt method as described previously [28], normalized to
those of 18S ribosomal RNA, and then expressed as fold changes relative
to those of control livers.
2.7. Immunoblot analysis
Preparation of whole liver lysates was carried out as described
previously [29]. Protein concentration was measured colorimetrical-
ly with BCA protein assay kit (Thermo Fisher Scientiﬁc, Rockford, IL,
USA). Whole liver lysates (20 μg of protein) were subjected to sodi-
um dodecyl sulfate-polyacrylamide gel electrophoresis [30]. Three
samples from each group were loaded into each electrophoresis
assay and all samples were examined. After electrophoresis, proteins
were transferred to nitrocellulose membranes and incubated with
primary antibodies (1:200 dilution) against medium-chain and
very-long-chain acyl-coenzyme A (CoA) dehydrogenase (ACADM
and ACADVL, respectively), acyl-CoA oxidase 1 (ACOX1), PPARα
and δ (PPARA and PPARD, respectively), sterol regulatory element-
binding protein 1 (SREBF1), c-Jun-N-terminal kinase (JNK), and
phosphorylated JNK (p-JNK) purchased from Santa Cruz Biotechnol-
ogy Inc. (Dallas, TX, USA), followed by alkaline phosphatase-
conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Laborato-
ries, West Grove, PA, USA). Bands of β-actin and histone H1 were
used as loading controls for ACADM/ACADVL/ACOX1/JNK/p-JNK
and PPARA/PPARD/SREBF1, respectively. Band intensities weremeasured densitometrically, normalized to those of loading control,
and subsequently expressed as fold changes relative to those of
normal control livers.
2.8. Assays for DNA-binding activity of PPARs
The DNA-binding activity of nuclear PPARα, PPARδ, and PPARγwas
determined using PPARα, PPARδ, and PPARγ Transcription Factor Assay
kits (Cayman Chemical, Ann Arbor, MI, USA), respectively. These assays
are based on an enzyme-linked immunosorbent assay using PPAR re-
sponse element-immobilized microplates and speciﬁc PPAR antibodies,
thus offering similar results to those from the conventional radioactive
electrophoretic mobility shift assay. DNA-binding assays were carried
out according to the manufacturer's instructions using 50 μg of protein
prepared as described elsewhere [31]. Results are expressed as fold
changes relative to those of normal livers.
2.9. Statistical analysis
Statistical analyses were performed using SPSS software version
17.0 for Windows (SPSS, Chicago, IL, USA) and Stat Flex version.6
for Windows (ARTECH, Osaka, Japan). Clinical parameters were
expressed as median (range) or number (percentage) and the others
values were presented as mean ± SEM. For parametric variables,
comparisons between groups were made using the one-way
ANOVA with Bonferroni's correction. For nonparametric continuous
variables, the Kruskal–Wallis test was used and followed by the
Mann–Whitney U-test with Bonferroni's correction. Categorical
variables were analyzed by the Fisher's exact probability test.
Correlation coefﬁcients were calculated using Spearman's rank
Fig. 1. Representative liver histology of CTLN2. Samples were stained with the hematoxylin and eosin (upper and middle rows) or Azan–Mallory method (lower row). Original magniﬁ-
cation;×20 (upper and lower rows) and × 100 (middle row), respectively. Arrows indicate central vein.
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statistically signiﬁcant.
3. Results
3.1. CTLN2 patients having hepatic steatosis exhibit a lean phenotype
All liver samples from 16 CTLN2 patients had steatosis. Ten patients
were histologically diagnosed as having mild steatosis and the remain-
ing 6 patients had severe steatosis. Clinical features of normal control
group (n= 7) and CTLN2 patients withmild steatosis (n= 10) and se-
vere steatosis (n = 6) are summarized in Table 1. In the mild steatosis
group, BMI was lower than that of the control group. In the severe
steatosis group, bodyweight, BMI, andwaist circumferencewere signif-
icantly lower than those in the control group. In CTLN2 patients, serum
levels of aspartate and alanine aminotransferases (AST and ALT, respec-
tively), ammonia, and citrulline were signiﬁcantly higher than those of
the control group. Hepatic ASS activities were reduced in CTLN2 pa-
tients as reported previously [32], but there were no signiﬁcant differ-
ences between the mild and severe steatosis groups.
Representative liver histology is demonstrated in Fig. 1 and histolog-
ical ﬁndings are summarized in Table 2. Steatotic hepatocytes were
present mainly around central vein and the grade of steatosis and
NAFLD activity score were signiﬁcantly different between the groups.Table 2
Histological ﬁndings of livers.
Normal Mild steatosis Sever
(N = 7) (N = 10) (N =
NAFLD activity score 0 (0–0) 2 (1–3) 4 (3–
Steatosis (%) 0 (0–0) 20 (5–30) 70 (6
Steatosis 0/1/2/3 7/0/0/0 0/10/0/0 0/0/1
Lobular inﬂammation 0/1/2/3 7/0/0/0 4/6/0/0 0/6/0
Ballooning 0/1/2 0/0/0 8/2/0 5/1/0
Fibrosis 0/1A/1B/1C/2/3/4 7/0/0/0/0/0/0 5/3/0/2/0/0/0 2/2/0
The steatosis/lobular inﬂammation/ballooning/ﬁbrosis gradeswere scored according to the criteria
of less than 0.05 was underlined.In CTLN2 patients, the grade of lobular inﬂammation was signiﬁcantly
higher than that of the control group. Only 3 patients (19%) were diag-
nosed ashaving steatohepatitis. The stage ofﬁbrosiswasnot statistically
different among the groups.
The degree of steatosis was correlated with serum levels of ALT
(r = 0.415, P = 0.031) and citrulline (r = 0.638, P = 0.002) and
was inversely correlated with body weight (r = −0.580, P =
0.004), BMI (r = −0.617, P = 0.002), waist circumference
(r = −0.675, P b 0.001), and serum albumin concentrations
(r =−0.626, P = 0.002) (Supplementary Fig. 1). These results cor-
roborate previous observations that CTLN2-related fatty liver is not
accompanied by obesity and visceral fat accumulation.
3.2. Hepatic FA/TG metabolism is disrupted in CTLN2 patients
To examine the mechanism of steatogenesis in CTLN2 patients,
hepatic mRNA levels of genes associated with FA uptake, transport
and activation were determined. The mRNAs encoding CD36,
FA-binding protein 1 (FABP1), and long-chain acyl-CoA synthetase
(ACSL1) were signiﬁcantly decreased in the CTLN2 groups compared
with the control group (Fig. 2A). The CD36, FABP1, and ACSL1 mRNAs
in the severe steatosis CTLN2 group were lower than those in the mild
steatosis CTLN2 group (Fig. 2A). FAs are catabolized through
β-oxidation in the mitochondria, peroxisomes, and ω-oxidation ine steatosis P value
6) Normal vs mild Normal vs severe Mild vs severe
5) b0.001 b0.001 b0.001
0–80) – – –
/5 0.004 0.043 0.015
/0 0.035 b0.001 0.234
0.925 0.861 0.884
/1/0/1/0 0.937 0.928 1.000
proposed by Kleiner et al.[27]. Results are expressed asmedian (range) or number. A p value
Fig. 2.Down-regulation of hepatic FAβ-oxidation enzymes andMTTP in CTLN2. (A) ThemRNAs encoding genes associatedwith FA/TGmetabolism. HepaticmRNA levelswere normalized
to those of 18S ribosomal RNA and then expressed as fold changes relative to those of the normal group. (B) Immunoblot analysis of ACADM, ACADVL and ACOX1. A representative im-
munoblot is shown. β-actin was used as the loading control. (C) Band intensities were measured densitometrically, normalized to those of β-actin, and then expressed as fold changes
relative to those of normal livers. (D and E) Serum levels of ketone bodies (D) and malondialdehyde (MDA, E). Results were expressed as mean ± SEM. Comparisons between groups
were made using the one-way ANOVA with Bonferroni's correction. Black bar, normal controls (n = 7); Gray bar, mild steatosis CTLN2 group (n = 10); White bar, severe steatosis
CTLN2 group (n = 6). ⁎P b 0.05 compared with normal controls; #P b 0.05 compared with mild steatosis group.
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CoA transferase 1A (CPT1A), carnitine-acylcarnitine carrier (CAC,
encoded by SLC25A20), ACADM, and ACADVL, which are enzymes/pro-
teins responsible for mitochondrial β-oxidation, were signiﬁcantly de-
creased in CTLN2 groups and further decreased in the severe steatosis
group (Fig. 2A). Similar changes were observed in the mRNAs encoding
peroxisomal β-oxidation enzymes, such as ACOX1 (ACOX1) and acetyl-
CoA acyltransferase 1 (ACAA1), and a microsomal ω-oxidation enzyme
cytochrome P450 4A11 (CYP4A11) (Fig. 2A).
There were no signiﬁcant changes in the mRNA encoding enzymes
associated with lipogenesis, such as FA synthase (FASN), acetyl-CoA
carboxylases α and β (ACACA and ACACB, respectively), ATP citrate
lyase (ACLY), and diacylglycerol-O-acyltransferases 1 and 2 (DGAT1 and
DGAT2, respectively), among the 3 groups (Fig. 2A). Although themRNA levels encoding apolipoprotein B (APOB) and hepatic lipase
(LIPC) were not altered among the groups, the mRNAs encoding micro-
somal TG transfer protein (MTTP), a key protein transporting TG from
the liver as very-low-density lipoprotein, were signiﬁcantly suppressed
in CTLN2 livers and further decreased in CTLN2 livers showing severe
steatosis (Fig. 2A).
The mRNA levels of the genes down-regulated in CTLN2 livers were
inversely correlated with the severity of steatosis (Supplementary
Fig. 2). These results suggest that down-regulation of FA oxidation-
associated enzymes and MTTP is associated with TG accumulation in
the livers of CTLN2.
The changes in FA oxidation were assessed further by immunoblot
analyses revealing signiﬁcant reductions in the expression of ACADM,
ACADVL and ACOX1 in the liver of CTLN2 patients that are consistent
Fig. 3. Down-regulation of hepatic PPARα in CTLN2. (A) Hepatic mRNA levels of PPARs/
RXRA/SREBF1. The same samples used in Fig. 2 were adopted. (B) Immunoblot analysis
of PPARs and SREBF1. A representative immunoblot is shown. Histone H1 was used as
the loading control. (C) Band intensities were measured densitometrically, normalized
to those of histone H1, and then expressed as fold changes relative to those of normal
livers. (D) PPARα DNA-binding activity based on an enzyme-linked immunosorbent
assay. Binding activity levels were expressed as fold changes relative to those of normal
livers. (E) Correlation between PPARAmRNA, PPARα DNA-binding activity, and severity
of steatosis. Results were expressed as mean ± SEM. Comparisons between groups were
made using the one-way ANOVA with Bonferroni's correction. Black bar, normal controls
(n=7);Gray bar,mild steatosis CTLN2 group (n=10);White bar, severe steatosis CTLN2
group (n = 6). ⁎P b 0.05 compared with normal controls; #P b 0.05 compared with mild
steatosis group. Correlation coefﬁcientswere calculatedusing Spearman's rank correlation
analysis.
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which are indicators of mitochondrial β-oxidation activity, sharply
declined in the CTLN2 patients (Fig. 2D). FA oxidation is coupled with
oxidative stress generation. Consistentwith down-regulation of FA oxida-
tion, circulating MDA levels were signiﬁcantly reduced in CTLN2 patients(Fig. 2E). Neither reductions in mRNAs encoding oxidative stress-
generating enzymes, such as xanthine dehydrogenase (XDH) and
NADPH oxidases (CYBB and NOX4), nor inductions in mRNAs encoding
oxidative stress-eliminating enzyme, including catalase (CAT) and super-
oxide dismutases (SOD1 and SOD2), were seen (Supplementary Fig. 3A).
Serum levels of ketone bodies and MDA were inversely correlated with
the degree of steatosis (Supplementary Fig. 3B). Collectively, these results
demonstrate that marked impairment of FA oxidation is associated with
the development of hepatic steatosis in the CTLN2 patients.3.3. Hepatic PPARα is down-regulated in CTLN2 patients
Since the expression of the genes involved in FA/TG metabolism is
regulated by several transcriptional factors, such as PPARs, retinoid X re-
ceptor α (RXRα), and SREBFs, the expression of these factors was
assayed. Although the PPARD, PPARG, RXRA, and SREBF1 mRNAs were
not different among the groups, PPARA mRNA was signiﬁcantly de-
creased in the CTLN2 groups comparedwith the controls. The decreases
were more marked in the severe steatosis group (Fig. 3A). Immunoblot
analysis and DNA-binding activity assays further revealed that PPARα
was functionally deﬁcient in these patients (Fig. 3B–D). PPARAmRNA
levels and PPARα-binding activities were inversely correlated with the
degree of steatosis (r=−0.684, P b 0.001 and r=−0.764, P b 0.001,
respectively) (Fig. 3E).
It was reported that PPARα regulates the transcriptional levels of
several genes, such as CD36, FABP1, ACSL1, CPT1A, SLC25A20, ACADM,
ACADVL, ACOX1, ACAA1, CYP4A11, and MTTP[31,33–37], all of which
are down-regulated in the livers of CTLN2 patients. Indeed, a strong cor-
relation was detected between PPARAmRNA levels and its target genes
(Supplementary Fig. 4). Therefore, down-regulation of hepatic PPARα
and the ensuing disruption of FA/TG metabolism were considered as a
mechanism of steatogenesis due to CD.3.4. Relationship between clinical parameters and hepatic PPARα expression
Hepatic PPARAmRNA levels were signiﬁcantly correlated with body
weight (r = 0.711, P b 0.001), BMI (r = 0.651, P b 0.001), waist
circumference (r= 0.600, P= 0.005), and serum albumin concentra-
tions (r = 0.569, P = 0.006) (Fig. 4A). Interestingly, PPARA mRNAs
were inversely correlated with circulating levels of ammonia
(r = −0.503, P = 0.031) and citrulline (r = −0.492, P = 0.037)
(Fig. 4A). However, there were no signiﬁcant correlations between
PPARA mRNA and serum AST or ALT levels. These results suggest a
close relationship between down-regulation of PPARα and clinical fea-
tures in CTLN2.3.5. Factors associated with down-regulation of hepatic PPARα in
CTLN2 patients
The causes of PPARα down-regulation in CTLN2 patients were
assessed. Inﬂammatory signaling, especially nuclear factor kappa B
(NF-κB) signaling, can suppress PPARα activity. Lobular inﬂammation
was detected in CTLN2 livers and increases in mRNAs of tumor necrosis
factor α (TNF) and the decreases in mRNAs for NF-κB inhibitor α
(NFKBIA) were seen in the severe steatosis group, but not in the mild
steatosis group (Fig. 4B). There were no meaningful changes in
mRNAs encoding other pro-inﬂammatory mediators, such as interleu-
kin (IL) 1B, IL6, and transforming growth factor β1 (TGFB1) (Fig. 4B).
Recently, it was documented that activation of JNK down-regulates
PPARα [38]. Immunoblot analysis revealed increased p-JNK in steatotic
livers of CTLN2 (Fig. 4C and D). Therefore, JNK activation is one of the
possible molecular mechanisms that could suppress the PPARα activity
caused by CTLN2.
Fig. 4. Factors associated with down-regulation of PPARα in CTLN2. (A) Correlation between PPARAmRNA levels and clinical parameters. Correlation coefﬁcients were calculated using
Spearman's rank correlation analysis. (B) Hepatic mRNA levels of genes associated with inﬂammation. The same samples used in Fig. 2 were adopted. (C) Immunoblot of JNK. The
same samples used in Fig. 2 were subjected to immunoblot analysis. (D) Band intensities were measured densitometrically, normalized to those of β-actin, and then expressed as fold
changes relative to those of normal livers. Results were expressed as mean ± SEM. Comparisons between groups were made using the one-way ANOVA with Bonferroni's correction.
Black bar, normal control (n = 7); Gray bar, mild steatosis CTLN2 group (n = 10); White bar, severe steatosis CTLN2 group (n = 6). ⁎P b 0.05 compared with normal controls;
#P b 0.05 compared with mild steatosis group.
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In the present study, the mechanism of steatogenesis accompanied
by CTLN2 was examined and signiﬁcant down-regulation of genes
encoding FA oxidation enzymes and MTTP was found in the patients'liver. Serum concentrations of ketone bodies, an indicator of mitochon-
drial β-oxidation activity, were also signiﬁcantly decreased in CTLN2
patients and were inversely correlated with the severity of steatosis.
Furthermore, PPARα, the main regulator of FA oxidation, wasmarkedly
suppressed in these patients, likely due to JNK activation. These results
480 M. Komatsu et al. / Biochimica et Biophysica Acta 1852 (2015) 473–481indicate that down-regulation of PPARα is associated with hepatic
steatosis in CTLN2 patients.
The transcriptional levels of several FA-metabolizing enzymes/pro-
teins are directly regulated by PPARα [33,39–42]. Mice lacking the
Ppara gene demonstrate constitutively low expression of FA-oxidizing
enzymes and signiﬁcant decreases in FA oxidation activity, leading to
severe steatosis and hypoketonemia by fasting [43]. Down-regulation
of PPARα and its target genes, such as FABP1, was also reported in
human non-alcoholic steatohepatitis (NASH), which is consistent with
the results of the current study [44]. The fact that Mttp mRNA levels
are not decreased in Ppara-null mice [41] suggests that the contribution
of PPARα toMTTP expression is not as strong as that of the FA-oxidizing
enzymes, such as ACADM and ACADVL.
The precise molecular mechanisms on how PPARα is down-
regulated in the livers of CTLN2 patients need to be discussed. A recent
report demonstrated that forced overexpression of JNK by adenovirus
suppressed the PPARαmRNA levels in cultured cardiac myocytes [38].
Additionally, pre-treatment with a JNK inhibitor to cultured cardiac
myocytes inhibited TNFα-induced PPARα down-regulation without af-
fecting inﬂammatory signaling [38]. These ﬁndings suggest that JNK ac-
tivation is a possible mechanism for PPARα down-regulation in CTLN2
patients. FA accumulation due to PPARα down-regulation may activate
JNKprobably through a direct effect on FA and/or endoplasmic reticulum
stress [45,46], leading to a vicious cycle of down-regulating PPARα and
further lowering FA oxidation activity. Enhancement of inﬂammatory
signaling found in CTLN2 livers with severe steatosis might be also asso-
ciated with reductions in PPARα activity to some degree. Additionally, it
was documented that hepatic expression of enzymes involved in
ureagenesis, such as carbamoyl-phosphate synthase, ornithine
transcarbamoylase, and ASS, was suppressed by PPARα activation in
mice [47]. These ﬁndings suggest that down-regulation of PPARαmay
be an adaptive response to urea cycle disruption.
CTLN2 is one of the major urea cycle disorders [7,13]. Urea cycle
disorders are sometimes accompanied by hepatic steatosis [1,48]. As
far as we know, this is the ﬁrst report demonstrating a link between a
urea cycle disorder, hepatic steatosis, and down-regulation of FA
oxidation and PPARα. To convert 1 mol of NH4+ to urea, 3 mol of
ATP is required. Mitochondrial β-oxidation can generate ATP more
efﬁciently than glycolysis, but hepatic ATP levels may already be low
in CTLN2 livers due to a severe decline in PPARα signaling and
mitochondrial β-oxidation activity. Although down-regulation of
PPARαmight be compensation for urea cycle disruption atﬁrst, the per-
sistent and signiﬁcant down-regulation may be coupled with further
decreases in hepatic ATP contents and impairment of the urea cycle,
resulting in hyperammonemia. The peculiar fondness of fat-rich diet
seen in CTLN2 patients [13,16] might be an adaptive response to obtain
more ATP through FA oxidation. Based on the results in this study,
strategies to enhance mitochondrial β-oxidation activity and increase
hepatic ATP levels may be beneﬁcial for moderating metabolic
abnormalities in CTLN2.
The present study provides several points that need further investi-
gation. First, the molecular mechanism of PPARα down-regulation
caused by CD/CTLN2, especially the involvement of JNK signaling,
should be determined using suitable mouse models or cell culture ex-
periments. Second, the effect of PPARα agonist on CTLN2-related fatty
liver needs to be evaluated. Indeed, a beneﬁcial effect of bezaﬁbrate on
CTLN2-related hypertriglyceridemia has been reported [49]. Lastly, the
method detecting the alterations in PPARα-regulated pathways may
provide new clues to more accurately evaluate the severity of CTLN2.
Untargeted metabolomic approaches using serum/urine would be a
promising tool [50].
In conclusion, hepatic PPARα and FA oxidation are signiﬁcantly
down-regulated in CTLN2 patients. This study demonstrates a
novel mechanism of steatogenesis caused by CD and proposes a con-
nection between urea cycle disorder and disruption of PPARα signal-
ing and lipid metabolism in the liver.Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.12.011.
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